Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)

Sponsor
Johns Hopkins University
Study ID
NCT00407719
Phase
PHASE1
Status
Completed

Conditions

  • Choroidal Neovascularization
  • Degenerative Myopia
  • Pathological Myopia

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to see if the drug bevacizumab is safe and effective to use for people with choroidal neovascularization (CNV). CNV is an eye condition where abnormal blood vessels grow in the part of the eye responsible for central (straight ahead) vision. The drug is produced using recombinant DNA technology and has been approved by the FDA for use in colon cancer. Although not yet approved for people with CNV, the FDA has given permission to use this drug in this study.

Key Dates

First listed
Dec 5, 2006
Start date
Jun 30, 2005
Status verified
Jan 2009
Primary completion
Apr 30, 2007
Completion
May 31, 2008

Study Design

Enrollment
10 participants
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Primary Outcome Measure

Visual acuity: In this pilot study, the sample size is not powered for clinical response. However, preliminary data on visual acuity will aid in the design of future randomized control trial. [ Time Frame: each visit for study duration up to 24 mos ]

Related Studies